Conferred resistance to the therapeutic combination by wild-type BRAF was also confirmed in two independent and genetically similar colon cancer cell lines, DLD-1 and HCT116 (Figure S3), indicating only wild-type BRAF as the exclusionary factor for colon cancer treatment with PLX4720. This evidence concerns the gene BRAF and colonic neoplasm.